Literature DB >> 12407724

Lymphatic spread among women with primary peritoneal carcinoma.

Gamal H Eltabbakh1, Sharon L Mount.   

Abstract

BACKGROUND AND OBJECTIVES: Our knowledge regarding the pathologic lymphatic spread pattern of primary peritoneal carcinoma (PPC) is limited. The aim of this study was to compare the incidence and the pathologic patterns of pelvic and para-aortic lymph node metastases among women with PPC and those with papillary serous ovarian carcinoma (PSOC).
METHODS: We conducted a prospective study over the last 4 years among women with FIGO stage III and IV PPC and PSOC who had optimal primary cytoreductive surgery (<1 cm residual). The same surgeon performed pelvic and para-aortic lymphadenectomy on all the patients using a similar technique. The same pathologist reviewed all lymph nodes and recorded nodal involvement with cancer, diameter of the largest nodal tumor, capsular integrity, and pattern of immune response (lymphocyte predominant, germinal cell predominant, unstimulated, or lymphocyte depletion). Both groups were compared in their characteristics, FIGO stage, tumor grade, number of lymph nodes, proportion of lymph nodes with metastases, and the pathologic characteristics of the positive lymph nodes.
RESULTS: Eleven women had PPC and 27 had PSOC. Patients with PPC were older than those with PSOC (mean age: 63.2 years +/- 11.0 vs. 57.4 +/- 13.4, P = 0.181). There was no difference in FIGO stage or tumor grade between both groups. There was no difference among the mean numbers of pelvic and para-aortic lymph nodes between women with PPC and those with PSOC (10.8 +/- 7.3 vs. 11.0 +/- 6.7 and 3.0 +/- 3.3 vs. 3.4 +/- 2.1, P = 0.768 and 0.706, respectively). The incidences of pelvic, para-aortic, and pelvic and/or para-aortic lymph node metastases were similar among women with PPC and those with PSOC (72.7% vs. 66.6%, P = 0.701, 72.7% vs. 48.1%, P = 0.172, and 72.7% vs. 77.8%, P = 0.736, respectively). Similarly, pelvic and para-aortic nodal tumor size, capsular integrity, and immune response were similar in both groups. The incidence of significant complications related to lymphadenectomy was low among women with PPC and those with PSOC (9.1% vs. 7.4%, respectively).
CONCLUSIONS: PPC and PSOC exhibit similar pathologic lymphatic spread patterns. Pelvic and para-aortic lymphadenectomy should be considered among women with PPC in whom the tumor could be optimally cytoreduced. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12407724     DOI: 10.1002/jso.10166

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Recent progress in the diagnosis and treatment of ovarian cancer.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  CA Cancer J Clin       Date:  2011-04-26       Impact factor: 508.702

2.  A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.

Authors:  Holger Moch; Alwin Krämer; Chantal Pauli; Tilmann Bochtler; Linda Mileshkin; Giulia Baciarello; Ferran Losa; Jeffrey S Ross; George Pentheroudakis; George Zarkavelis; Suayib Yalcin; Mustafa Özgüroğlu; Andreas Beringer; Jeremy Scarato; Mathis Mueller-Ohldach; Marlene Thomas
Journal:  Oncologist       Date:  2021-03-25

3.  Extraovarian Primary Peritoneal Carcinomatosis: A Case Report.

Authors:  Gregory Nicolas; Tony Kfoury; Hassan Fawaz; Mahdi Issa
Journal:  Am J Case Rep       Date:  2017-06-26

4.  Development and Validation of Prognostic Nomogram for Primary Peritoneal Serous Carcinoma Compared With FIGO Staging System: A Population-Based Study.

Authors:  Ming Chen; Zhenzhen Wen; Zhengwei Qi; Min Gao
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244

5.  Inguinal Lymph Node Metastasis of a Primary Serous Papillary Carcinoma of the Peritoneum One Year after CRS and HIPEC.

Authors:  Shadi Katou; Mathilde Feist; Wieland Raue; Johann Pratschke; Beate Rau; Andreas Brandl
Journal:  Visc Med       Date:  2018-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.